Lundin Law PC ( announces that it is investigating claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (Nasdaq: SPPI) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at

The investigation focuses on a statement by Spectrum that it failed to disclose that the Food & Drug Administration advised it not to submit a New Drug Application for its drug candidate apaziquone back in December of 2012.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010